Compare AbbVie Inc (ABBV) vs Ford Motor Company (F) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Ford Motor Company (F) trades at $13.57, up 1.65% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative net income margin and ROE. Recent developments include a strategic semiconductor supply agreement with Micron and vehicle recalls affecting over 110,000 Mustang models. Operating cash flow remains robust at $21.28 billion for 2025, though net income turned negative at -$8.18 billion.

Ford presents a value opportunity with attractive valuation ratios (P/E 11.84, P/S 0.29) but faces significant execution risks. The stock trades below analyst consensus target of $15.00, offering potential upside, though recent sales declines and profitability concerns warrant caution. Key catalysts include EV strategy execution and truck demand strength, while risks include competitive pressures and operational challenges.